We are live on !
Find out more
BVF Inc Portfolio holdings
AUM
$3.91B
Turnover
15.22%
1-Year Est. Return
304.52%
This Fund
S&P 500
This Quarter Est. Return
+55.74%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.93%
10 Year Est. Return
+28,184.7%
AUM
$531M
AUM Growth
+$61.3M
(+13%)
Cap. Flow
-$27.5M
Cap. Flow % of AUM
Cap. Flow %
-5.17%
Top 10 Holdings %
Top 10 Hldgs %
72.14%
Holding
37
New
3
Increased
6
Reduced
15
Closed
8
Avg Time Held
1.4
years
Top 10 Avg Time Held
1.5
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
|
+$11.3M |
| 2 |
Xenon Pharmaceuticals
XENE
|
+$10.3M |
| 3 |
IMDZ
Immune Design Corp.
IMDZ
|
+$8.77M |
| 4 |
OMED
OncoMed Pharmaceuticals, Inc.
OMED
|
+$5.5M |
| 5 |
Protagonist Therapeutics
PTGX
|
+$5.13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ionis Pharmaceuticals
IONS
|
+$19.8M |
| 2 |
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
|
+$9.5M |
| 3 |
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
|
+$8.21M |
| 4 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
+$8M |
| 5 |
Array Biopharma Inc
ARRY
|
+$6.96M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.35% |
| 2 | Miscellaneous | 0.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Blueprint Medicines
BPMC
| $82.1M | 15.48% |
2,765,080
-130,171
| -4% | -$3.23M |
2015 Q2
5 quarters
|
|
2
DELISTED
ChemoCentryx, Inc.
CCXI
| $48.7M | 9.18% |
8,064,019
-118,033
| -1% | -$558K |
2013 Q2
13 quarters
|
|
3
Cytokinetics
CYTK
$7.68B
| $45.9M | 8.64% |
4,997,071
+7,853
| +0.2% | +$82K |
2013 Q2
13 quarters
|
|
|
4
DELISTED
Array Biopharma Inc
ARRY
| $43.6M | 8.22% |
6,461,186
-1,799,711
| -22% | -$6.96M |
2013 Q2
13 quarters
|
|
|
CASC
5
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $30.8M | 5.81% |
3,133,228
| – | – |
2013 Q2
13 quarters
|
|
|
FWP
6
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| $29.1M | 5.49% |
198,265
-5,251
| -3% | -$739K |
2014 Q4
7 quarters
|
|
|
CLCD
7
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
| $29.1M | 5.49% |
+763,300
| New | +$11.3M |
2016 Q3
0 quarters
|
|
|
CNCE
8
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $27.5M | 5.19% |
2,723,210
-32,108
| -1% | -$351K |
2014 Q3
8 quarters
|
|
|
9
Xenon Pharmaceuticals
XENE
$3.92B
| $25.2M | 4.75% |
3,108,905
+1,333,333
| +75% | +$10.3M |
2014 Q4
7 quarters
|
|
|
OMED
10
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $20.7M | 3.9% |
1,812,005
+472,669
| +35% | +$5.5M |
2013 Q3
12 quarters
|
|
11
Crescent Biopharma
CBIO
$507M
| $17.3M | 3.27% |
24,263
-211
| -0.9% | -$161K |
2016 Q2
1 quarter
|
|
|
CTIC
12
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $16.8M | 3.16% |
4,479,694
| – | – |
2015 Q3
4 quarters
|
|
|
TBRA
13
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
| $15.9M | 2.99% |
399,433
-853,968
| -68% | -$9.5M |
2013 Q3
12 quarters
|
|
14
DELISTED
Alpine Immune Sciences Inc
ALPN
| $13.9M | 2.62% |
427,418
-54,193
| -11% | -$1.32M |
2015 Q4
3 quarters
|
|
|
ARQL
15
DELISTED
Arqule Inc
ARQL
| $13.2M | 2.5% |
7,400,128
-50,000
| -0.7% | -$79.3K |
2013 Q2
13 quarters
|
|
16
CytomX Therapeutics
CTMX
$432M
| $9.28M | 1.75% |
591,813
-14,325
| -2% | -$173K |
2015 Q4
3 quarters
|
|
|
IMDZ
17
DELISTED
Immune Design Corp.
IMDZ
| $9.1M | 1.71% |
+1,200,000
| New | +$8.77M |
2016 Q3
0 quarters
|
|
18
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $9.01M | 1.7% |
8,223
| – | – |
2014 Q4
7 quarters
|
|
|
INFI
19
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $8.03M | 1.51% |
5,149,644
-34,956
| -0.7% | -$53.7K |
2016 Q2
1 quarter
|
|
|
20
Protagonist Therapeutics
PTGX
$8.79B
| $7.92M | 1.49% |
+375,000
| New | +$5.13M |
2016 Q3
0 quarters
|
|
21
DELISTED
Esperion Therapeutics
ESPR
| $6.84M | 1.29% |
493,872
-5,270
| -1% | -$59.7K |
2016 Q1
2 quarters
|
|
|
KDNY
22
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $6.23M | 1.17% |
100,231
-2,490
| -2% | -$176K |
2016 Q2
1 quarter
|
|
23
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $3.19M | 0.6% |
20,867
-2,053
| -9% | -$290K |
2015 Q3
4 quarters
|
|
|
OREX
24
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $2.44M | 0.46% |
734,976
+209,766
| +40% | +$792K |
2016 Q2
1 quarter
|
|
25
Filana Therapeutics
FLNA
$24.8M
| $2.28M | 0.43% |
325,507
+18,377
| +6% | +$304K |
2015 Q3
4 quarters
|
|
Similar funds
LFCM
AC
BVF Inc's Q3 2016 Portfolio in Review
As of Q3 2016, BVF Inc held 37 positions worth $531M, up 13% from $469M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
BVF Inc withdrew a net $27.5M in Q3 2016, closing 8 positions and reducing 15 holdings. Its most notable exit was Ionis Pharmaceuticals, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 91% a quarter earlier, followed by Miscellaneous.
Against the trend, BVF Inc opened a new position in CoLucid Pharmaceuticals, Inc. worth $29.1M.
- BVF Inc's largest Q3 2016 buy was CoLucid Pharmaceuticals, Inc.: 763,300 shares worth $29.1M.
- BVF Inc added most to Xenon Pharmaceuticals in Q3 2016, an estimated $10.3M increase.
- BVF Inc's biggest Q3 2016 reduction was Tobira Therapeutics, Inc. Common Stock, cutting an estimated $9.5M.
- BVF Inc fully exited Ionis Pharmaceuticals in Q3 2016, selling an estimated $19.8M.
- BVF Inc's ten largest holdings make up 72% of its $531M portfolio in Q3 2016.
- BVF Inc opened 3 new positions and closed 8 in Q3 2016.
- BVF Inc's portfolio value rose 13% quarter-over-quarter to $531M.
Based on BVF Inc's 13F filing for Q3 2016, filed 14 Nov 2016.